reSET digital therapeutic

Pear Therapeutics to offer its digital therapeutics through telehealth partners

The company's first telehealth offering is with PursueCare to offer patients an end-to-end virtual continuum of comprehensive addiction recovery care.
Pear Therapeutics homepage

Pear Therapeutics ended 2021 with $4.2M in revenue, expects $22M this year

Yes, the digital therapeutics market is taking off...
Pear Therapeutics homepage

Digital therapeutics company Pear Therapeutics to go public in a $1.6B SPAC deal

The deal provides additional investment to capitalize on Pear's position by investing in the commercialization of its three FDA-authorized products.
Pear Therapeutics homepage

Pear Therapeutics licenses multiple technologies to bolster its PDT platform

The company has expanded its platform with digital biomarkers, machine learning algorithms and sensor-based technologies.

Pear Therapeutics launches Somryst for chronic insomnia

Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
reSET-O dashboard

Pear Therapeutics publishes real-world utilization data for reSET-O

Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
Pear Therapeutics reSET and reSET-O

PreferredOne taps Pear to become the first health plan to cover digital therapeutics

PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.

Sandoz, Pear Therapeutics launch reSET to treat SUD patients

Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone.
PEAR Therapeutics reSET

Magellan Health to pilot PEAR Therapeutics’ digital therapeutic reSET

The pilot program will enroll 250 patients with Substance Use Disorders (SUD) and offer each patient a 12-week course of reSET therapy.
Pear Therapeutics

Pear Therapeutics gets $20M for its prescription digital therapies

The company will use the money to build and launch a portfolio of eFormulations, including reSET and reSET-O, for treating substance use disorder.